{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T21:33:20Z","timestamp":1747172000308,"version":"3.40.5"},"reference-count":62,"publisher":"Elsevier BV","issue":"35","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,5,11]],"date-time":"2015-05-11T00:00:00Z","timestamp":1431302400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"European Union FP7"},{"DOI":"10.13039\/501100000781","name":"European Research Council (ERC)","doi-asserted-by":"publisher","award":["324634"],"award-info":[{"award-number":["324634"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.vaccine.2015.04.086","type":"journal-article","created":{"date-parts":[[2015,6,6]],"date-time":"2015-06-06T11:21:04Z","timestamp":1433589664000},"page":"4349-4358","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Market implementation of the MVA platform for pre-pandemic and pandemic influenza vaccines: A quantitative key opinion leader analysis"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1846-1510","authenticated-orcid":false,"given":"Bahar","family":"Ramezanpour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther S.","family":"Pronker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joost H.C.M.","family":"Kreijtz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert D.M.E.","family":"Osterhaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Claassen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2015.04.086_bib0315","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1016\/j.vaccine.2013.05.091","article-title":"Utilizing poxviral vectored vaccines for antibody induction-progress and prospects","volume":"31","author":"Draper","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0320","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1128\/CMR.00097-12","article-title":"Traditional and new influenza vaccines","volume":"26","author":"Wong","year":"2013","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0325","unstructured":"TNIoAaID (2013) Types of Vaccines. Vaccinesgov, http:\/\/www.vaccines.gov\/more_info\/types\/."},{"issue":"Suppl. 4","key":"10.1016\/j.vaccine.2015.04.086_bib0330","doi-asserted-by":"crossref","first-page":"D145","DOI":"10.1016\/j.vaccine.2011.09.003","article-title":"From smallpox eradication to the future of global health: innovations, application and lessons for future eradication and control initiatives","volume":"29","author":"Tomori","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0335","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.coviro.2012.02.010","article-title":"Rinderpest eradication: lessons for measles eradication?","volume":"2","author":"de Swart","year":"2012","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0340","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.2105\/AJPH.2010.300051","article-title":"Images of health, smallpox: the first vaccine","volume":"101","author":"Roth","year":"2011","journal-title":"Am J Public Health"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0345","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.immuni.2010.10.004","article-title":"Immunologic basis of vaccine vectors","volume":"33","author":"Liu","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0350","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s12033-011-9450-2","article-title":"Development of vaccine delivery vehicles based on lactic acid bacteria","volume":"51","author":"Tarahomjoo","year":"2012","journal-title":"Mol Biotechnol"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0355","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1128\/JVI.02386-13","article-title":"The canarypox virus vector ALVAC induces distinct cytokine responses compared to the vaccinia virus-based vectors MVA and NYVAC in rhesus monkeys","volume":"88","author":"Teigler","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0360","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1016\/j.vaccine.2013.03.021","article-title":"Recombinant MVA, vaccines: dispelling the myths","volume":"31","author":"Cottingham","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0365","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1016\/j.vaccine.2013.06.073","article-title":"Poxvirus vectors","volume":"31","author":"Kreijtz","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0370","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.coi.2011.03.006","article-title":"Viral vectors as vaccine platforms: deployment in sight","volume":"23","author":"Rollier","year":"2011","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0375","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1016\/j.vaccine.2013.03.042","article-title":"Reflections on the early development of poxvirus vectors","volume":"31","author":"Moss","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0380","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2174\/156652311795684731","article-title":"MVA and NYVAC as vaccines against emergent infectious diseases and cancer","volume":"11","author":"Gomez","year":"2011","journal-title":"Curr Gene Ther"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0385","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1016\/j.vaccine.2013.03.016","article-title":"Protective efficacy of modified vaccinia virus Ankara in preclinical studies","volume":"31","author":"Volz","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0390","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1016\/j.vaccine.2013.03.020","article-title":"Clinical development of modified vaccinia virus Ankara vaccines","volume":"31","author":"Gilbert","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0395","first-page":"6","article-title":"Modified vaccinia virus Ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases","author":"Altenburg","year":"2014","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0400","article-title":"Imvanex, modified vaccinia Ankara virus","author":"EMA","year":"2013","journal-title":"EMA Sci Med Health"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0405","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1099\/vir.0.024885-0","article-title":"Evaluation of a modified vaccinia virus Ankara (MVA)-based candidate pandemic influenza A\/H1N1 vaccine in the ferret model","volume":"91","author":"Kreijtz","year":"2010","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0410","first-page":"4","article-title":"Preclinical evaluation of influenza vaccines based on replication-deficient poxvirus vector MVA","author":"Rimmelzwaan","year":"2011","journal-title":"Procedia Vaccinol"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0415","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/0264-410X(94)90341-7","article-title":"A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus","volume":"12","author":"Sutter","year":"1994","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0420","doi-asserted-by":"crossref","first-page":"6418","DOI":"10.1128\/JVI.70.9.6418-6424.1996","article-title":"Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza","volume":"70","author":"Bender","year":"1996","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0425","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/ciq015","article-title":"Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1","volume":"52","author":"Berthoud","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0430","doi-asserted-by":"crossref","first-page":"e62778","DOI":"10.1371\/journal.pone.0062778","article-title":"Examination of influenza specific T cell responses after influenza virus challenge in individuals vaccinated with MVA-NP+M1 vaccine","volume":"8","author":"Powell","year":"2013","journal-title":"PLOS ONE"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0435","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jenvman.2003.09.010","article-title":"Evaluating the management strategies of a forestland estate--the S-O-S approach","volume":"69","author":"Kangas","year":"2003","journal-title":"J Environ Manage"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0440","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.sbspro.2012.09.1139","article-title":"Application of combined SWOT and AHP: a case study for a manufacturing firm","volume":"58","author":"G\u00f6rener","year":"2012","journal-title":"Procedia Soc Behav Sci"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0445","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1057\/palgrave.ejis.3000679","article-title":"Prioritization of e-government strategies using a SWOT\u2013AHP analysis: the case of Turkey","volume":"16","author":"Kahraman","year":"2007","journal-title":"Eur J Inf Syst"},{"year":"1980","series-title":"The analytic hierarchy process","author":"Saaty","key":"10.1016\/j.vaccine.2015.04.086_bib0450"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0455","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0024-6301(96)00095-7","article-title":"SWOT analysis: its time for a product recall","volume":"30","author":"Hill","year":"1997","journal-title":"Long Range Plan"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0460","first-page":"71","article-title":"Decision making for leaders: the analytical hierarchy process for decisions in a complex world","volume":"2","author":"Saaty","year":"1982","journal-title":"Anal Hierarchy Process Ser"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0465","first-page":"83","article-title":"Decision making with the analytic hierarchy process","volume":"1","author":"Saaty","year":"2008","journal-title":"Int J Serv Sci"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0470","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.smr.2010.12.003","article-title":"SWOT and AHP hybrid model for sport marketing outsourcing using a case of intercollegiate sport","volume":"14","author":"Lee","year":"2011","journal-title":"Sport Manag Rev"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0475","doi-asserted-by":"crossref","first-page":"510","DOI":"10.47102\/annals-acadmedsg.V37N6p510","article-title":"Vaccines for pandemic influenza, the history of our current vaccines, their limitations and the requirements to deal with a pandemic threat","volume":"37","author":"Hampson","year":"2008","journal-title":"Ann Acad Med Singap"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0480","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.2165\/11209650-000000000-00000","article-title":"A\/H5N1 prepandemic influenza vaccine (whole virion, vero cell-derived, inactivated) [Vepacel(R)]","volume":"72","author":"Plosker","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0485","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/BF03261899","article-title":"A\/H5N1 prepandemic influenza vaccine (Vepacel(R)): a guide to its use","volume":"26","author":"Keating","year":"2012","journal-title":"BioDrugs"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0490","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(09)62039-0","article-title":"Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial","volume":"375","author":"Vajo","year":"2010","journal-title":"Lancet"},{"year":"2009","series-title":"Adjupanrix (previously Pandemic influenza vaccine (H5N1)) (split virion, inactivated, adjuvanted)","author":"EMA","key":"10.1016\/j.vaccine.2015.04.086_bib0495"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0500","doi-asserted-by":"crossref","first-page":"17","DOI":"10.32607\/20758251-2012-4-4-17-27","article-title":"Recombinant influenza vaccines","volume":"4","author":"Sedova","year":"2012","journal-title":"Acta Nat"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0505","doi-asserted-by":"crossref","first-page":"e49704","DOI":"10.1371\/journal.pone.0049704","article-title":"A randomized clinical trial of an inactivated avian influenza A (H7N7) vaccine","volume":"7","author":"Couch","year":"2012","journal-title":"PLoS ONE"},{"year":"2009","series-title":"Focetria, influenza vaccine (H1N1) (surface antigen, inactivated, adjuvanted)","author":"EMA","key":"10.1016\/j.vaccine.2015.04.086_bib0510"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0515","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.vaccine.2012.01.016","article-title":"Recombinant protein vaccines produced in insect cells","volume":"30","author":"Cox","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0520","doi-asserted-by":"crossref","first-page":"411","DOI":"10.4161\/hv.18757","article-title":"Virus-like particle (VLP)-based vaccines for pandemic influenza: performance of a VLP vaccine during the 2009 influenza pandemic","volume":"8","author":"Lopez-Macias","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0525","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1089\/vim.2011.0016","article-title":"Baculovirus-produced influenza virus-like particles in mammalian cells protect mice from lethal influenza challenge","volume":"24","author":"Tang","year":"2011","journal-title":"Viral Immunol"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0530","doi-asserted-by":"crossref","first-page":"7826","DOI":"10.1016\/j.vaccine.2011.07.099","article-title":"Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico","volume":"29","author":"Lopez-Macias","year":"2011","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2015.04.086_bib0535","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1186\/1471-2458-13-S3-S14","article-title":"An evaluation of the emerging vaccines against influenza in children","volume":"13 Suppl","author":"Nair","year":"2013","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0540","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.3390\/v6083055","article-title":"Virus-vectored influenza virus vaccines","volume":"6","author":"Tripp","year":"2014","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0545","doi-asserted-by":"crossref","first-page":"A40","DOI":"10.1016\/j.vaccine.2011.04.122","article-title":"Live attenuated pandemic influenza vaccine: clinical studies on A\/17\/California\/2009\/38 (H1N1) and licensing of the Russian-developed technology to WHO for pandemic influenza preparedness in developing countries","volume":"29 Suppl 1","author":"Rudenko","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0550","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.2165\/11206860-000000000-00000","article-title":"Live attenuated influenza vaccine (FluMist(R); Fluenz): a review of its use in the prevention of seasonal influenza in children and adults","volume":"71","author":"Carter","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0555","doi-asserted-by":"crossref","first-page":"15ra15","DOI":"10.1126\/scitranslmed.3000624","article-title":"Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus","volume":"2","author":"Khurana","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0560","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(09)62003-1","article-title":"Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial","volume":"375","author":"Liang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0565","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/cid\/cir334","article-title":"Clinical applications of DNA vaccines: current progress","volume":"53","author":"Ferraro","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0570","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1128\/CVI.05663-11","article-title":"Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans","volume":"19","author":"Ledgerwood","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0575","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1016\/j.vaccine.2010.01.029","article-title":"Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin","volume":"28","author":"Smith","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0580","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S1473-3099(14)70963-6","article-title":"Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1\/2a clinical trial","volume":"14","author":"Kreijtz","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0585","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1586\/14760584.2013.811178","article-title":"Clinical vaccine development for H5N1 influenza","volume":"12","author":"Clegg","year":"2013","journal-title":"Expert Rev Vacci"},{"year":"2007","series-title":"Alternative procedures for deriving value functions based on point scales and AHP. Technical note, Centre for Traffic and Transport","author":"Barfod","key":"10.1016\/j.vaccine.2015.04.086_bib0590"},{"year":"1998","series-title":"Decision Analysis for Management Judgment","author":"Goodwin","key":"10.1016\/j.vaccine.2015.04.086_bib0595"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0600","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.1016\/j.vaccine.2013.03.017","article-title":"Modified Vaccinia virus Ankara: innate immune activation and induction of cellular signalling","volume":"31","author":"Price","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.04.086_bib0605","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nrmicro2240","article-title":"Viruses as vaccine vectors for infectious diseases and cancer","volume":"8","author":"Draper","year":"2010","journal-title":"Nat Rev Microbiol"},{"year":"2013","series-title":"Imvanex, modified vaccinia Ankara virus","author":"EMA","key":"10.1016\/j.vaccine.2015.04.086_bib0610"},{"year":"2011","series-title":"Influenza vaccines therapeutics \u2013 pipeline assessment and market forecast to 2018","author":"GlobalData","key":"10.1016\/j.vaccine.2015.04.086_bib0615"},{"year":"2012","series-title":"ARCAS: Analysis of the route to commercialisation of MVA based influenza vaccines","author":"Osterhaus ADME","key":"10.1016\/j.vaccine.2015.04.086_bib0620"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15005721?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15005721?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T06:00:48Z","timestamp":1691733648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15005721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":62,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0264410X15005721"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.04.086","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Market implementation of the MVA platform for pre-pandemic and pandemic influenza vaccines: A quantitative key opinion leader analysis","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.04.086","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}